1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECH
  4. LIANBIO - ADR
LianBio - ADR XNAS: LIANY

Watchlist

Portfolio

Alert

Share
Board Meeting
The next board meeting for LianBio - ADR is on 17 Jul 2025 for the purpose of LianBio First Quarter Earnings Results for 2025 See details


Insider Trading disclosures for LianBio - ADR

The latest disclosure was made by Adam Stone in LianBio - ADR where a trade of 19,218 Ordinary Shares done at an average price of $4.8 was reported to US exchanges on Feb. 15, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Adam Stone Director, Interim CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. 15 Feb 2024 19,218 17,082 - 4.8 91,478 Ordinary Shares
Konstantin Poukalov Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Feb 2024 36,300 0 - - Stock Option (Right to Buy)
Poukalov Konstantin Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. 15 Feb 2024 36,300 36,300 - 2.5 91,476 Ordinary Shares
Silbermann Susan Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Feb 2024 36,300 0 - - Stock Option (Right to Buy)
Silbermann Susan Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. 15 Feb 2024 36,300 36,300 - 2.5 91,476 Ordinary Shares
Adam Stone Director, Interim CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. 15 Feb 2024 36,300 36,300 - 2.5 91,476 Ordinary Shares
Poukalov Konstantin Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. 15 Feb 2024 19,218 17,082 - 4.8 91,478 Ordinary Shares
Adam Stone Director, Interim CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Feb 2024 36,300 0 - - Stock Option (Right to Buy)
Silbermann Susan Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. 15 Feb 2024 19,218 17,082 - 4.8 91,478 Ordinary Shares
Ehong Gu Interim CFO Sale of securities on an exchange or to another person at price $ 4.34 per share. 02 Jan 2024 1,731 76,762 - 4.3 7,513 Ordinary Shares
Ehong Gu Interim CFO Sale or transfer of securities back to the company at price $ 0.32 per share. 02 Jan 2024 17,889 0 - 0.3 5,724 Ordinary Shares
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters